by SWK Holdings | Sep 27, 2023 | 2023
Guest Column | September 27, 2023 By Jody Staggs, president and CEO, SWK Holdings Small life science companies are the driving force behind groundbreaking medical innovations that have the potential to transform lives. Yet in a market with strong headwinds, securing...
by SWK Holdings | Sep 21, 2023 | 2023
Introduction The SWK underwriting process generally consists of an approximate four-week diligence period followed by an approximate four-week legal documentation process. Key steps in SWK’s process include data review, key opinion leader (“KOL”) calls, customer...
by SWK Holdings | Jul 6, 2022 | 2022
Guest Column originally published in Outsourced Pharma, June 29, 2022 The Federal Reserve’s move to raise interest rates to battle inflation – now running at approximately 8% annually – has altered the risk and return for investors who are dealing with rising...
by SWK Holdings | Jun 30, 2022 | 2022
The primary motivation for growth stage companies to explore venture debt as a source of funding is to avoid the dilution that results from a round of equity financing. While venture debt will certainly be much less dilutive than an equity raise, prospective borrowers...
by SWK Holdings | Dec 17, 2021 | 2021
At SWK, we believe that financial covenants and the process of setting mutually agreeable covenant levels play an important role in the lender/borrower relationship. A lender’s willingness to engage in the discussions and accommodate the requests outlined herein...
by SWK Holdings | Nov 15, 2021 | 2021
Factors to Consider When Choosing a Lender The four corners of the credit agreement will contain all of the important contractual terms and conditions to which a lender and borrower have agreed to be bound. The language will dictate what is required of each party in...
by SWK Holdings | Sep 28, 2021 | 2021
Capacity is one of the five C’s of credit which refers to a borrower’s ability to repay a loan’s principal and interest. For early-stage companies, the capacity to repay is markedly more uncertain than for larger, more established businesses. The presence of...
by SWK Holdings | Sep 8, 2021 | 2021
As underwriting standards loosen during periods when capital markets become increasingly favorable to borrowers, an easing, or outright elimination of financial covenants invariably follows. Regardless of the lending environment, credit agreements will contain...
by SWK Holdings | Feb 21, 2019 | Case Study
In December 2012 SWK acquired a limited partnership interest in Holmdel Pharmaceuticals Holmdel subsequently acquired the U.S. marketing authorization rights to InnoPran XL, a non-selective beta blocker using dosing technology to provide maximum active ingredient...
by SWK Holdings | Feb 21, 2019 | Case Study
Narcan is the only FDA approved, intranasal Naloxone product for the treatment of opioid overdose Narcan is appropriately priced with revenue growth due to a differentiated nasal dosing and expanded distribution, not price hikes Opiant is a publicly traded drug...
